ANDA 213583, held by Specgx LLC. Amphetamine Sulfate.
As of Nov 16, 2026, ANDA 213583 (Amphetamine Sulfate), held by Specgx LLC, was first approved by FDA on Jan 22, 2021, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 22, 2021 | Original application | Approved | None posted |
| Amphetamine Sulfate5MG · tablet;oral | Amphetamine Sulfate | Rx |
| Amphetamine Sulfate10MG · tablet;oral | Amphetamine Sulfate | Rx |
| Oct 18, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 25, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 22, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters